ARCT Q2 2024 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+337.1% YoY

Gross Profit

$46M100.0% margin

Operating Income

-$21M-46.0% margin

Net Income

-$17M-37.4% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+41.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$389M

Total Liabilities

$130M

Stockholders' Equity

$259M

Cash & Equivalents

$315M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$11M	+337.1%
Gross Profit	$46M	$7M	+578.3%
Operating Income	-$21M	-$55M	+61.8%
Net Income	-$17M	-$53M	+67.2%

Revenue Segments

Collaboration Revenue

$46M92%

Grant

$4M8%